RCS - Ondine Biomedical - Ondine continues commercial growth

Ondine BiomedicalAnnouncement

28/10/2024 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20241028:nRSb7735Ja&default-theme=true

RNS Number : 7735J  Ondine Biomedical Inc.  28 October 2024

ONDINE BIOMEDICAL INC.

("Ondine Biomedical", "Ondine" or the "Company")

Ondine continues commercial growth

Ondine Biomedical Inc. (LON: OBI), the Canadian life sciences company
pioneering light-activated antimicrobial treatments, announces that it has
made significant progress with the commercial roll-out of its novel nasal
decolonization technology, Steriwave(®), in both Canada and the UK. Steriwave
is a simple 5-minute procedure that reduces healthcare-associated infections
(HAIs) by rapidly decolonizing the nose without the use of antibiotics or
generating antimicrobial resistance (AMR).

In the UK, two of the largest NHS Trusts, King's College Hospital NHS Trust
(https://www.londonstockexchange.com/news-article/OBI/king-s-college-hospital-to-run-steriwave-pilot/16727459)
and Leeds Teaching Hospitals NHS Trust
(https://www.londonstockexchange.com/news-article/OBI/leeds-teaching-hospital-nhs-trust-to-use-steriwave/16603858)
, are initiating Steriwave treatment prior to surgery. Recently Ondine
announced that has partnered with Mölnlycke Health Care
(https://www.molnlycke.com/corporate/news/media-room/molnlycke-and-ondine-join-forces-against-hais/)
, a world-leading MedTech company that specializes in innovative solutions for
wound care and surgical procedures, to bring Ondine's Steriwave® nasal
decolonization technology to the United Kingdom, EU, and Middle East markets.

In Canada, Steriwave is being used routinely in five (half) of the country's
top 10 largest hospitals: Royal Alexandra (Alberta), The Ottawa Hospital -
Civic Campus (Ontario), Vancouver General (BC), University of Alberta
Hospital, and the Queen Elizabeth II Hospital (Nova Scotia). 1  In the last
few months, five additional Canadian healthcare facilities have started using
Steriwave to decolonize patients undergoing orthopedic surgery. These include
University Hospital of Northern British Columbia, Royal Inland Hospital, Eagle
Ridge Hospital, Okanagan Health Surgery Centre, and Hawkesbury General
Hospital.

Steriwave is also being used in all five of British Columbia's Health
Authorities and benefitting from expanding regional adoption. For example,
Royal Inland is the fourth hospital in Canada's British Columbia Interior
Health Authority to adopt Steriwave alongside Kelowna General, Penticton
Regional, and Kootenay Boundary. Eagle Ridge Hospital became the third
hospital to embrace Steriwave in the Fraser Health Authority, following
Burnaby Hospital, one of the largest hospitals outside the city of Vancouver
and the Royal Columbian Hospital, which will be the first hospital to trial
Steriwave to prevent infections in ICUs
(https://ondinebio.com/collaboration-advances-steriwave-for-icu-market/) . The
four major hospitals in the Vancouver Coastal Health Authority - the first to
adopt nasal photodisinfection - have deployed Steriwave in their presurgical
infection prevention protocols.

Nicole Walby, Clinical Operations Manager at Interior Health Authority,
commented:

"Steriwave has been fully embraced by patients and staff alike, with patients
and their families feeling reassured by the added protection. It's made a
noticeable difference at our facility, bringing a sense of ease and comfort to
an otherwise serious environment. Preventing surgical site infection through
important tools such as Steriwave is a top priority for our clinicians in
upholding and improving patient experiences."

One in nine hospital patients in Canada gets an HAI resulting in approximately
12,000 deaths a year. 2  HAIs are also becoming harder to treat due to rising
rates of AMR which are making some commonly used antibiotics ineffective. 3 
This has meant that one in 19 deaths in Canada is now attributable to
antibiotic-resistant infections. 4  The cost of AMR to the Canadian healthcare
sector is also projected to increase from $1.4 billion to $7.6 billion per
year by 2050.(( 5 ))

Steriwave is a novel antimicrobial treatment that uses a proprietary
light-activated agent to decolonize the nose and rapidly eliminate
infection-causing pathogens. The agent is applied to each nostril using a
nasal swab and then illuminated with a specific wavelength of red light. The
light activates the photodynamic agent, causing an oxidative burst that
destroys infection-causing bacteria, viruses and fungi in a single, 5-minute
treatment. The process works so rapidly that pathogens do not have the
opportunity to develop resistance, making it a viable alternative to
antibiotics.

 

About Ondine Biomedical Inc.

 

Ondine Biomedical Inc. is a Canadian life sciences company and leader in
light-activated antimicrobial therapies (also known as 'photodisinfection').
Ondine has a pipeline of investigational products, based on its proprietary
photodisinfection technology, in various stages of development.

 

Ondine's nasal photodisinfection system has a CE mark in Europe and is
approved in Canada and several other countries under the name Steriwave(®).
In the US, it has been granted Qualified Infectious Disease Product
designation and Fast Track status by the FDA and is currently undergoing
clinical trials for regulatory approval. Products beyond nasal
photodisinfection include therapies for a variety of medical indications such
as chronic sinusitis, ventilator-associated pneumonia, burns and other
indications.

 

About Steriwave

 

Steriwave is a groundbreaking antimicrobial treatment that uses a
light-activated antimicrobial agent to rapidly eliminate a broad spectrum of
pathogens, including bacteria, viruses, and fungi. The treatment is
administered in a simple two-step process: first, the agent is applied to each
nostril with a nasal swab, followed by illumination with a specific wavelength
of red light. The light activates the agent, causing an oxidative burst that
destroys pathogens within the single 5-minute treatment, offering a robust
alternative to traditional antibiotics without the risk of developing
resistance.

 

Nasal decolonization is recommended in the 2016 WHO Global guidelines for the
prevention of surgical site infections, 6  and the Society for Healthcare
Epidemiology of America (SHEA) guidelines, published in May 2023, recommend
nasal decolonization for major surgical procedures. 7 

 

Enquiries:

 Ondine Biomedical Inc.
 Carolyn Cross, CEO                        +001 (604) 665 0555

 Singer Capital Markets

(Nominated Adviser and Joint Broker)
 Phil Davies, Sam Butcher                  +44 (0)20 7496 3000

 RBC Capital Markets (Joint Broker)
 Rupert Walford, Kathryn Deegan            +44 (0)20 7653 4000

 Vane Percy & Roberts (Media Contact)
 Simon Vane Percy, Amanda Bernard          +44 (0)77 1000 5910

 

 

 

 1  Definitive Healthcare: "Top 10 Largest Canadian Hospitals"
https://www.definitivehc.com/resources/healthcare-insights/top-largest-canadian-hospitals
(https://www.definitivehc.com/resources/healthcare-insights/top-largest-canadian-hospitals)

 2 
https://cupe.ca/health-care-associated-infections-backgrounder-and-fact-sheet
(https://cupe.ca/health-care-associated-infections-backgrounder-and-fact-sheet)

 3  Poovelikunnel T, Gethin G, Humphreys H. Mupirocin resistance: clinical
implications and potential alternatives for the eradication of MRSA. J
Antimicrob Chemother. 2015 Oct;70(10):2681-92. doi: 10.1093/jac/dkv169. Epub
2015 Jul 3.

 4  Healthcare-associated infections and antimicrobial resistance in Canadian
acute care hospitals, CCDR 49(5) - Canada.ca

 5  Healthcare-associated infections and antimicrobial resistance in Canadian
acute care hospitals, CCDR 49(5) - Canada.ca

 6  Surgical Site Infection Prevention: Key facts on decolonization of nasal
carriers of Staphylococcus aureus. World Health Organization. (link
(https://cdn.who.int/media/docs/default-source/integrated-health-services-(ihs)/ssi/fact-sheet-staphylococcus-web.pdf?sfvrsn=7e7266ed_2)
)

 7  Calderwood MS, Anderson DJ, Bratzler DW, et al. Strategies to prevent
surgical site infections in acute-care hospitals: 2022 Update. Infect Control
Hosp Epidemiol. 2023;44(5):695-720. (link
(https://www.cambridge.org/core/journals/infection-control-and-hospital-epidemiology/article/strategies-to-prevent-surgical-site-infections-in-acutecare-hospitals-2022-update/2F824B9ADD6066B29F89C8A2A127A9DC)
)

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAUBAURSOURUUA